首页 | 本学科首页   官方微博 | 高级检索  
     


Comparison of long-term clinical outcome after successful implantation of Firebird sirolimus- and Taxus paclitaxel-eluting stents in Chinese population: analysis of a large single center registry
Authors:DOU  Ke-fei XU  Bo YANG  Yue-jin CHEN  Ji-lin QIAO  Shu-bin WANG  Yang LI  Jian-jun QIN  Xue-wen YAO  Min LIU  Hai-bo WU  Yong-jian CHEN  Jue YUAN  Jin-qing YOU  Shi-jie LI  Wei GAO  Run-lin
Affiliation:Department of Cardiology, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
Abstract:Background Recent studies have shown that drug eluting stent (DES) implantation improved clinical outcome concerning efficacy compared with bare-metal stent (BMS) implantation, and sirolimus-eluting stent (SES) seemed superior to paclitaxel-eluting stent (PES) in improving the outcomes. Firebird SES is the most widely used SES in China. Long-term comparison of safety and efficacy between Firebird SES and Taxus PES in Chinese popuation is still not available. The aim of this research was to compare the safety and efficacy at 24 months after the successful implantation of Firebird SES and TAXUS PES in Chinese population.Methods From April 2004 to October 2006, 3110 consecutive patients who underwent successful DES (Firebird SES 2274; Taxus PES 836) implantation were prospectively enrolled into this study. All enrolled patients were divided into two groups based on stent type. By outpatient clinic visit and telephone interview, we obtained 24-month clinical outcome including death, myocardial infarction (Ml), thrombosis, target lesion revascularization (TLR), target vessel revascularization (TVR), and major adverse cardiac events (MACE, the composite of death, Ml, and TVR). We used Cox's proportional-hazards models to assess relative risks of all the outcome measures before and after propensity match. Results Unadjusted clinical outcomes indicated that the patients treated with Firebird SES were associated with lower risk of TLR (HR0.38, 95%CI 0.26-0.54), TVR (HR 0.51,95%CI 0.38-0.68) and MACE (HR 0.53, 95%CI 0.41-0.68). The results after propensity match were consistent with that before matching, lower risk of TLR (HR 0.33, 95%CI 0.19-0.58), TVR (HR 0.41, 95%CI 0.26-0.64), MACE (HR 0.48, 95%CI 0.33-0.68) in Firebird group.Conclusion Compared with Taxus PES, the use of domestic Firebird SES may decrease the risk of TLR, TVR and MACE in daily practice.
Keywords:treatment outcome  Firebird sirolimus-eluting stent  Taxus paclitaxel-eluting stent
本文献已被 维普 万方数据 等数据库收录!
点击此处可从《中华医学杂志(英文版)》浏览原始摘要信息
点击此处可从《中华医学杂志(英文版)》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号